-
Orexigen Shares Up 14% After Commercialization, Distribution Deal With Valeant Canada
Tuesday, August 30, 2016 - 9:49am | 346Read More...Orexigen Therapeutics, Inc. (NASDAQ: OREX) and Valeant Canada, a subsidiary of Valeant Pharmaceuticals Intl Inc (NYSE: VRX), struck an agreement on commercialization and distributorship for Contrave. Following the news, Orexigen traded up by more than 12 percent in the pre-market trading. Orexigen...
-
Leerink Comments On Orexigen Therapeutics, Says Current Projections Could Prove To Be 'Conservative'
Wednesday, March 4, 2015 - 1:01pm | 110Read More...In a report published Wednesday, Leerink analyst Paul Matteis commented on Orexigen Therapeutics, Inc. (NASDAQ: OREX) and wrote that following a positive opinion from the CHMP, the company expects a final opinion from the EMA on the Mysimba (Contrave) marketing authorization application. Matteis...
